Yeah, when I looked over their (Greenhill) website under healthcare companies, it appears that the vast majority of transactions were mergers & acquisitions. They handled the $46.9 billion acquisition of Genentech by Roche, and a couple of other transactions by Roche. My expectations are very tempered right now; I was not incredibly impressed with the CC but it also sounded to me like the typical analyst nitpicking stuff, which is all over my head. I have to chalk this up to further need for patience and let this thing play out.
It is kind of interesting that Roche had to drop their diabetes drug trials on aleglitazar last month due to health/side effect concerns. Maybe they will have an interest in Afrezza to pick up slack in pipeline.
